Category Archives: Generics / ANDA

Amgen, Inc. et al. v. Hospira, Inc.

Docket No. 2016-2179 DYK, BRYSON, CHEN August 10, 2017 Brief summary: Amgens’s appeal for lack of jurisdiction and petition for a writ of mandamus dismissed and denied, respectively, since DC denial of Amgen’s motion to compel discovery is “reviewable from … Continue reading

Posted in Biosimilars, Generics / ANDA | Leave a comment

Millenium Pharmaceuticals, Inc. v. Sandoz Inc. et al.

Docket No. 2015-2066 (several others) NEWMAN, MAYER, O’MALLEY July 17, 2017 Brief summary: DC decision that claims related to Millenium’s Velcade® are invalid for obviousness vacated and remanded. Summary: Millenium appealed DC decision that claims 20, 31, 49 and 53 … Continue reading

Posted in Generics / ANDA, Obviousness, Obviousness-Teaching Away | Leave a comment

Braintree Laboratories, Inc. v. Breckenridge Pharmaceutical, Inc.

Docket No. 2016-1731 NEWMAN, MOORE, WALLACH May 5, 2017 Non-precedential Brief Summary: DC claim construction (e.g., previous Novel decision “foreclosed the [DC’s] construction of ‘from about 100 ml to about 500 ml’”) and infringement decisions reversed (e.g., claimed effects of … Continue reading

Posted in Claim Construction, Generics / ANDA, Inducement to Infringe, Infringement | Leave a comment

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. et al.

Docket No. 2016-1284, -1787 DYK, MAYER, O’MALLEY May 1, 2017 Brief Summary: FC panel reversed DC and found the asserted claims invalid under the § 102(b) on-sale bar. The FC panel concluded that the AIA did not change the meaning … Continue reading

Posted in America Invents Act, Anticipation (35 USC 102), Generics / ANDA, On-Sale Bar | Leave a comment

The Medicines Company v. Mylan, Inc. et al.

Docket No. 2015-1113, -1151, -1181 DYK, WALLACH, HUGHES April 6, 2017 Brief Summary: DC’s finding of infringement of the ‘727 patent reversed based on FC’s reading its construction of “efficient mixing” into the claims, thereby requiring infringing batches to “be … Continue reading

Posted in Claim Construction, Generics / ANDA | Leave a comment

Shire Development, LLC et al. v. Watson Pharmaceuticals, Inc. et al.

Docket No. 2016-1785 PROST, TARANTO, HUGHES February 10, 2017 Brief Summary: DC decision that Watson’s ANDA Product to Shire’s Lialda® reversed for not meeting the Markush requirements of the claims. Summary: Shire sued Watson for infringement of US 6,773,720 directed … Continue reading

Posted in Claim Construction, Generics / ANDA, Infringement | 2 Comments

Mylan Laboratories Ltd. v. Aventis Pharma S.A.

IPR2016-00627 August 23, 2016 Brief Summary: Mylan’s Petition requesting IPR regarding claims 1 and 2 of Aventis’ US 5,847,170 encompassing the taxoid cabazitaxel (Jevtana®) denied. Summary: Mylan filed a Petition requesting IPR of claims 1 and 2 of Aventis’ US … Continue reading

Posted in Generics / ANDA, Inter Parties Review (IPR), IPR, Obviousness | Leave a comment